EPCAM and prostate carcinoma: Indeed, IFNγ treatment significantly increased PD-L1 cell surface expression in the Pten-null CAP2 and CAP8 prostate cancer cells (Supplementary Fig. 8A), and RNA-seq analysis on the EpCAM+ cancer cells isolated from BAY-I treated and withdrawal group demonstrated that the expression of PD-L1 was significantly increased in these two cohorts (Fig. 8B).